Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will attend one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors should contact their Piper Sandler representative to arrange meetings.
Key Figures
- Conference date
- April 16, 2026
- Piper Sandler Spring Biopharma Symposium one-on-one meetings
- Announcement date
- April 14, 2026
- Press release publication date
Historical Context
-
First patient dosed in Phase 1b/2a CT2000 eye pain trial.
-
Q4 and full-year 2025 results with revenue growth and new financings.
-
Announcement of date and call details for Q4 and 2025 results.
-
CEO presentation and one-on-ones at Oppenheimer healthcare conference.
-
Up to $50M Horizon term loan to fund commercialization and launches.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors interested in arranging one-on-one meetings should contact their Piper Sandler representative.
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel,
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.